Migdal Insurance Financial Holdings Ltd. adds Vascular Biogenics Ltd (VBLT) to its portfolio

Vascular Biogenics Ltd (VBLT) : Migdal Insurance Financial Holdings Ltd. added new position in Vascular Biogenics Ltd during the most recent quarter end. The investment management firm now holds 400,000 shares of Vascular Biogenics Ltd which is valued at $1,700,000 , the company said in a statement filed on Aug 3, 2016 with the SEC.Vascular Biogenics Ltd makes up approximately 0.05% of Migdal Insurance Financial Holdings Ltd.’s portfolio.

Other Hedge Funds, Including , Smith Asset Management Group Lp sold out all of its stake in VBLT during the most recent quarter. The investment firm sold 20,690 shares of VBLT which is valued $82,760. Cutler Group Lp added VBLT to its portfolio by purchasing 200 company shares during the most recent quarter which is valued at $790.

Vascular Biogenics Ltd closed down -0.11 points or -2.58% at $4.15 with 1,51,326 shares getting traded on Monday. Post opening the session at $4.23, the shares hit an intraday low of $4.12 and an intraday high of $4.23 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Many Wall Street Analysts have commented on Vascular Biogenics Ltd. H.C. Wainwright Initiated Vascular Biogenics Ltd on Jun 28, 2016 to “Buy”, Price Target of the shares are set at $11.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. The Company is developing VB-111 the lead oncology product candidate from its VTS platform technology which is a gene-based biologic for the treatment of solid tumor indications with clinical programs in recurrent glioblastoma (rGBM) thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *